



With the publication of the revised USP Chapter <797> which will go into effect November 1, 2023, the USP Chapter <800>, which directs processes to protect healthcare worker exposure from hazardous drugs, will also go into effect. The Joint Commission will incorporate compendially-applicable sections of the USP Chapter <800> within its survey process.

Many organizations are facing challenges when it comes to USP Chapters <797> and <800> compliance due to its many requirements and multidisciplinary work across the continuum of hazardous drug handling and sterile compounding. We understand that you recognize the urgency and importance to be compliant with these national standards but may lack the resources or expertise needed to overcome these challenges to achieve sustainable compliance to protect your staff who may come into contact with hazardous drugs and be in compliance with sterile compounding requirements.

Turn to the experts at JCR

Our Medication Management and Safety Advisory Services are here to help you face your USP Chapters <797> and <800> challenges. Our team of current and former pharmacy, nursing, and Environment of Care® and facility directors will perform a comprehensive assessment to evaluate compliance at your facility. They will identify where your organization has gaps with the USP Chapters <797> and <800> requirements and will provide suggestions and tools to help you implement an action plan to help bring your organization into compliance.

Environmental Assessment of your Compounding Site

New requirements for cleanrooms or segregated compounding areas are part of the USP 797 (rev) and USP 800 chapters. JCR consultants will evaluate your sterile compounding areas to determine whether gaps in performance exist or whether changes are required. JCR consultants can also review temporary compounding sites for workflow optimization if compounding is relocated at times of construction.

A plan tailored to your needs

Our experts, who are current or former pharmacists with expertise in helping organizations to achieve effective and sustainable improvements, will work with your organization to:

- Evaluate compliance for USP Chapters <797> and <800> requirements and provide recommendations to address findings and improve compliance
- Advise and support your organization in performing an Assessment of Risk as part of your USP Chapter <800> implementation strategy

- Assess hazardous drug sterile and non-sterile compounding environments to determine compliance with USP Chapter <800>
- Review organizational policies pertaining to sterile compounding requirements in USP Chapters <797> and <800>
- Assist and support you in the development of training and competency assessment programs that meet USP Chapters
 <797> and <800> requirements
- Assess cleanroom and sterile compounding hood certification reports to evaluate vendor performance and response to actionable findings
- Provide education and tools to support organizational compliance with USP Chapter <797> and USP Chapter <800>

At the end of this engagement with JCR, you'll receive:

- A comprehensive report highlighting findings, key priority areas for improvement, and organizational strengths
- A presentation to your team and management explaining the findings
- Tools to support ongoing compliance with USP Chapters
 <797> and <800>

To learn more, visit https://www.jcrinc.com/products-and-services/advisory-services/ or call 630.268.7400 and ask to speak to a client relations manager about Medication Management and Safety Advisory Services.

The use of Joint Commission Resources consultative technical or advisory services is not necessary to obtain a Joint Commission Accreditation award, nor does it influence the granting of such awards. JCR is an expert resource for health care organizations, providing advisory services, educational services, software, and publications to assist in improving quality and safety and to help in meeting the accreditation standards of The Joint Commission. JCR provides advisory services independently from The Joint Commission and in a fully confidential manner.